Harvest Fund Management Co. Ltd Purchases 2,021 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Harvest Fund Management Co. Ltd grew its position in United Therapeutics Co. (NASDAQ:UTHR) by 300.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,693 shares of the biotechnology company’s stock after buying an additional 2,021 shares during the period. Harvest Fund Management Co. Ltd’s holdings in United Therapeutics were worth $949,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of UTHR. Newbridge Financial Services Group Inc. bought a new stake in shares of United Therapeutics in the 4th quarter valued at about $25,000. Brooklyn Investment Group purchased a new position in shares of United Therapeutics in the 3rd quarter valued at approximately $33,000. MassMutual Private Wealth & Trust FSB raised its position in shares of United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 58 shares during the last quarter. Jones Financial Companies Lllp raised its position in shares of United Therapeutics by 678.9% in the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 258 shares during the last quarter. Finally, SBI Securities Co. Ltd. purchased a new position in shares of United Therapeutics in the 4th quarter valued at approximately $131,000. 94.08% of the stock is currently owned by institutional investors.

Insider Activity

In other news, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $371.05, for a total transaction of $3,710,500.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $956,195.85. The trade was a 79.51 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Nilda Mesa sold 255 shares of United Therapeutics stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the transaction, the director now directly owns 5,528 shares of the company’s stock, valued at approximately $1,966,696.56. This trade represents a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 90,255 shares of company stock valued at $32,614,521 in the last three months. 11.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts recently commented on UTHR shares. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and issued a $425.00 price objective on shares of United Therapeutics in a research report on Thursday, February 27th. Finally, UBS Group increased their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $388.25.

United Therapeutics Trading Down 1.6 %

UTHR opened at $313.60 on Friday. The firm has a market capitalization of $14.08 billion, a PE ratio of 13.77, a P/E/G ratio of 0.97 and a beta of 0.64. The firm has a 50 day moving average of $346.14 and a two-hundred day moving average of $357.34. United Therapeutics Co. has a 12-month low of $221.53 and a 12-month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same period in the previous year, the firm earned $4.36 EPS. As a group, analysts predict that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.